Hear the latest developments in thyroid pathology and oncology from nationally and internationally recognised experts in the field.

Join us for a two-day update on endocrine pathology, covering topics (TBC) including: 

  • The Thyroid Cancer ‘Epidemic’
  • Pathological criteria for papillary thyroid carcinoma
  • Surgical approaches to thyroid cancer & pathology
  • Reporting thyroid FNA cytology using the UK ‘Thy’ system
  • WHO 2017 Classification of thyroid tumours 2017; NIFTP, FTUMP, WDTUMP, WDCa-NOS (emphasis on diagnostic pitfalls)
  • Risk stratification of thyroid cancer
  • Pitfalls in thyroid diagnosis & medicolegal issues
  • The Thyroid Patient. What the oncologist needs from pathology
  • Update on new therapies & clinical trials for thyroid cancer
  • Multidisciplinary working in thyroid disease
  • MDT’s, datasets & UK national guidelines. 
  • Case based discussions

Who should attend?

Consultant pathologists and senior trainees reporting thyroid pathology.


Day 1 - Thursday 6th February 2020 (programme tbc)

  9.30     Registration

10.00     Introduction and welcome

10.05     The Thyroid Cancer ‘Epidemic’. Professor Manuel Sobrinho-Simoes, Porto 

10.30     WHO 2017- update on encapsulated follicular patterned lesions, NIFTP, FTUMP, WDTUMP, WDCa-NOS with emphasis on diagnostic pitfalls and how to avoid them. Professor Giovanni Tallini, Bologna 

11.30     Refreshments

12.00     Reporting thyroid FNA using the UK Thy system with emphasis on practical application. Dr Sarah Johnson, Newcastle 

12.40     Diagnosing papillary thyroid carcinoma with emphasis on non-encapsulated variants and illustrative cases. Dr Mufaddal Moonim, London 

13.20     Lunch

14.00     Risk stratification of thyroid cancer with emphasis on high grade cases and illustrative example. Dr Ronald Ghossein, New York 

14.50     Surgical approaches to thyroid cancer and what the surgeon needs from the pathologist before and after surgery. Mr Sabapathy Balasubramanian, Sheffield 

15.40     Refreshments

16.10     Unexpected pathology in the thyroid: case based discussions. Professor Giovanni Tallini and Professor Manuel Sobrinho-Simoes 

17.10     Closing remarks

Day 2 - Friday 7th February 2020 (programme tbc)

  9.00     Registration

  9.30     Welcome

  9.35     Pitfalls and medicolegal issues in thyroid diagnosis and how to avoid them, with illustrative cases. Dr Ronald Ghossein, New York

10.35     Refreshments

11.00     The thyroid cancer patient: what the oncologist needs from pathology and an update on new therapies and clinical trials. Professor Jonathan Wadsley, Sheffield 

11.55     Why the Thyroid Multidisciplinary Team is so important with emphasis on common practical issues. Dr David Poller, Portsmouth

12.55     Closing remarks

13.00     Meeting close


Online Bookings

RCPath & UKEPS Members: £288.00
Concessions: £150.00 Includes trainees, BMS, non-consultant Clinical Scientists, retired & nurses
Non-members: £357.00

Offline Bookings (cheque and invoice)

RCPath & UKEPS Members: £323.00
Concessions: £183.00 Includes trainees, BMS, non-consultant Clinical Scientists, retired & nurses
Non-members: £388.00


To be held at the Royal College of Pathologists, 6 Alie Street, London E1 8QT.


2nd Bi-Annual UK Endocrine Pathology Society/RCPath Endocrine Pathology Update

  • Professor Manuel Sobrinho-Simoes, Porto

    Manuel Sobrinho Simões, MD, PhD, HonFRCPath is Emeritus Professor of Pathology and Director of the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP). MSS was President of the European Society of Pathology from 1999 to 2001, after having been Secretary from 1989 to 1997. MSS is co-author of about 400 papers (h factor 60) and many chapters of the last editions (1988, 2004 & 2017) of the WHO Book on Endocrine Tumours. MSS was considered the most influential pathologist in 2015 by The Pathologist and co-created, in 1992, the on-going very active European School of Pathology.

  • Dr David Poller, Portsmouth

    Dr David Poller is a Consultant Pathologist & Reader in Pathology at The Queen Alexandra Hospital in Portsmouth. His interests are the pathology & cytology of thyroid & endocrine cancer with a number of publications in this area. Dr Poller is Treasurer and Membership Secretary of the UK Endocrine Pathology Society, and is a member of UK RCPath guideline and NCRI research groups that relate to diagnosis of thyroid cancer. He was member of The Endocrine Pathology Society’s NIFTP working group in 2015/6 and frequently lectures on thyroid disease & FNA thyroid cytology.

  • Dr Mufaddal Moonim, London

    Dr Mufaddal Moonim is consultant Histopathologist at Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London and prior to this worked for many years at the Tata Memorial Cancer center in Mumbai India. He is lead for Haematopathology and Endocrine Pathology at GSTT. He is also meetings secretary for the UK Endocrine Pathology Society (UKEPS) and co-author of the RCPath Adrenal tumour dataset. His interests include adrenal tumours, SDHB expression in Phaeochromocytoma, thyroid tumours, thyroid FNA and minimally invasive diagnostics.

  • Dr Sarah J Johnson, Newcastle upon Tyne

    Consultant Cyto/histopathologist at the Royal Victoria Infirmary in Newcastle upon Tyne. Lead for Endocrine Pathology for Newcastle upon Tyne Hospitals NHS Foundation Trust. Co-author of UK RCPath Endocrine Cancer Datasets, Thyroid Cytology Guidance document, Endocrine Tissue Pathways and Thyroid Cytology Audit Template. Author of publications on thyroid, parathyroid and NET pathology including ongoing thyroid cytology-histology correlation. Member of NCRI Thyroid Cancer Subgroup. Member of expert panel for ICCR datasets for thyroid and parathyroid cancer. President of UKEPS.

  • Professor Jon Wadsley, Sheffield

    Professor Wadsley was appointed as Consultant Clinical Oncologist at Weston Park Hospital, Sheffield in 2004. His clinical interests are in thyroid cancer, neuroendocrine tumours and pancreatic/biliary tract cancers, with a particular interest in molecular radiotherapy. His research mirrors these clinical interests, with a particular focus on thyroid cancer and neuroendocrine tumours. He currently chairs the NCRI Thyroid Cancer Subgroup and is Chief Investigator of the SELIMETRY trial. He is Clinical Director of the Sheffield Cancer Clinical Trials Centre, Cancer Specialty Lead for the Yorkshire and Humber Clinical Research Network and NIHR National Specialty Lead for Radiotherapy and Imaging